Research demonstrates that SIRT7, a histone deacetylase, protects against abdominal aortic aneurysm (AAA) formation by deacetylating serum response factor (SRF), which maintains vascular smooth muscle cell contractile function. SIRT7 is markedly downregulated in human AAA tissues, and its deficiency accelerates aneurysm progression through enhanced SRF degradation and pathological smooth muscle phenotype switching. Critically, the study shows that nicotinamide mononucleotide (NMN), a NAD+ precursor, pharmacologically activates SIRT7 and attenuates aortic dilation in animal models, suggesting NMN supplementation as a novel therapeutic strategy for AAA prevention.
For your business
NMN activated SIRT7 and reduced aortic dilation in animal AAA models, supporting its vascular protective potential.